DIANA (DNA-linked Inhibitor ANtibody Assay) is a novel ultra-sensitive multi-well plate based protein detection assay, which provides unique benefits in its two main areas of application:
1. Drug discovery
Screening of chemical libraries for inhibitors or ligands of the target protein with ultra-low false-negative and false-positive rates
2. Clinical diagnostics
Ultra-sensitive detection of active enzymes or receptors in a range of clinical samples
DIANA is a multi-well plate assay, where target protein is selectively captured to the solid carrier and then bound by a unique detection probe consisting of a small-molecule ligand linked to a DNA-oligonucleotide. Subsequently, the probe is detected and quantified by qPCR. For drug discovery, the assay utilizes competition between the probe and the test compounds to measure their binding affinity.
DIANA is straightforward to develop for new targets and easy to implement using standard laboratory equipment.
DIANA technology was developed by the team lead by Václav Navrátil in the laboratory of Dr. Jan Konvalinka at the Institute of Organic Chemistry and Biochemistry, Academy of Sciences in Prague. This institute has a global reputation and strong record in drug discovery.
In 2018, the spin-off company DIANA Biotechnologies, s.r.o. was established with the venture capital funding in order to deliver DIANA products to the market. The company is based in its own research facility in a biotechnology hub in Vestec near Prague.
We have assembled a strong team combining deep expertise in molecular biology, organic chemistry, biochemistry, data analysis and technology transfer.
Biomolecular Interaction Analysis Services
Lead Identification and Validation Services
DIANA Biotechnologies, s.r.o. has not received any reviews.
DIANA Biotechnologies, s.r.o. has not received any endorsements.